A Meta-analysis and The Cancer Genome Atlas Data of Prostate Cancer Risk and Prognosis Using Epithelial Cell Adhesion Molecule (EpCAM) Expression

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2019 Jul 21

PMID 31324239

Citations 12

Authors

Yu Hu

Qiong Wu

Jialin Gao

Yongrui Zhang

Yuantao Wang

Affiliations

Soon will be listed here.

Abstract

Background: Epithelial cell adhesion molecule (EpCAM) expression has been reported in many types of cancer, including prostate cancer (PCa). However, the role of EpCAM expression remains inconsistent. We conducted a meta-analysis to assess the clinicopathological and prognostic significance of EpCAM expression in PCa.

Methods: Publications were searched online using electronic databases. The available data were obtained from The Cancer Genome Atlas (TCGA). The odds ratios (ORs) or hazard ratios (HRs) with their 95% confidence intervals (CIs) were calculated.

Results: We identified seven studies in which immunohistochemistry was used and that included 871 prostatic tissue samples. EpCAM expression was significantly higher in PCa samples than in benign and normal tissue samples (OR = 77.93, P = 0.002; OR = 161.61, P < 0.001; respectively). No correlation of EpCAM overexpression with pT stage and lymph node metastasis was observed; however, EpCAM overexpression showed a significant correlation with Gleason score (OR = 0.48, P = 0.012) and bone metastasis (OR = 145.80, P < 0.001). Furthermore, TCGA data showed that EpCAM overexpression was not closely correlated with age, pT stage, lymph node metastasis, number of lymph node, prostate-specific antigen level, Gleason score, biochemical recurrence, and overall survival. Based on multivariate Cox proportional-hazards regression analysis, a significant correlation was observed between EpCAM overexpression and 5-year worse biochemical recurrence free-survival.

Conclusions: EpCAM overexpression may be correlated with the development of bone metastasis and worse biochemical recurrence free-survival of PCa. Further studies are needed to verify these findings.

Citing Articles

Proteomic-based stratification of intermediate-risk prostate cancer patients.

Zhong Q, Sun R, Aref A, Noor Z, Anees A, Zhu Y Life Sci Alliance. 2023; 7(2).

PMID: 38052461 PMC: 10698198. DOI: 10.26508/lsa.202302146.

SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A.

Gu R, Kim T, Song H, Sui Y, Shin S, Oh S JCI Insight. 2023; 8(20.

PMID: 37870957 PMC: 10619491. DOI: 10.1172/jci.insight.164990.

Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.

He M, Zhang D, Cao Y, Chi C, Zeng Z, Yang X Heliyon. 2023; 9(8):e19147.

PMID: 37664750 PMC: 10469587. DOI: 10.1016/j.heliyon.2023.e19147.

Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis.

Ding P, Chen P, Ouyang J, Li Q, Li S Front Oncol. 2023; 13:1242231.

PMID: 37664060 PMC: 10468606. DOI: 10.3389/fonc.2023.1242231.

Overexpression of , , and in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival.

Ceron R, Martinez A, Ramos C, De la Cruz A, Garcia A, Mendoza I Onco Targets Ther. 2023; 15:1583-1595.

PMID: 36606244 PMC: 9809418. DOI: 10.2147/OTT.S386562.

References

BALZAR M, Winter M, de Boer C, Litvinov S . The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl). 1999; 77(10):699-712. DOI: 10.1007/s001099900038. View

Henshall S, Afar D, Rasiah K, Horvath L, Gish K, Caras I . Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene. 2003; 22(38):6005-12. DOI: 10.1038/sj.onc.1206797. View

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

Zintzaras E, Ioannidis J . HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005; 21(18):3672-3. DOI: 10.1093/bioinformatics/bti536. View

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U . Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer. 2006; 94(1):128-35. PMC: 2361083. DOI: 10.1038/sj.bjc.6602924. View

Merseburger A, Kramer M, Hennenlotter J, Simon P, Knapp J, Hartmann J . Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate. 2007; 68(1):72-7. DOI: 10.1002/pros.20688. View

Prince S, Zeidman A, Dekel Y, Ram E, Koren R . Expression of epithelial cell adhesion molecule in gallbladder carcinoma and its correlation with clinicopathologic variables. Am J Clin Pathol. 2008; 129(3):424-9. DOI: 10.1309/H8JEEAEB69J3KYND. View

Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E . Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res. 2008; 14(18):5849-55. DOI: 10.1158/1078-0432.CCR-08-0669. View

Shim H, Yoon B, Cho N . Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol. 2009; 40(5):693-8. DOI: 10.1016/j.humpath.2008.10.013. View

10.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

11.

Mukherjee S, Richardson A, Rodriguez-Canales J, Ylaya K, Erickson H, Player A . Identification of EpCAM as a molecular target of prostate cancer stroma. Am J Pathol. 2009; 175(6):2277-87. PMC: 2789605. DOI: 10.2353/ajpath.2009.090013. View

12.

Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P . Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat. 2009; 123(3):701-8. PMC: 3042397. DOI: 10.1007/s10549-009-0671-z. View

13.

Mueller M, Hermann P, Heeschen C . Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed). 2009; 2(2):602-13. DOI: 10.2741/e117. View

14.

Salnikov A, Groth A, Apel A, Kallifatidis G, Beckermann B, Khamidjanov A . Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med. 2010; 13(9B):4023-33. PMC: 4516549. DOI: 10.1111/j.1582-4934.2009.00723.x. View

15.

Benko G, Spajic B, Kruslin B, Tomas D . Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol. 2011; 31(4):468-74. DOI: 10.1016/j.urolonc.2011.03.007. View

16.

Moldenhauer G, Salnikov A, Luttgau S, Herr I, Anderl J, Faulstich H . Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst. 2012; 104(8):622-34. DOI: 10.1093/jnci/djs140. View

17.

Ni J, Cozzi P, Duan W, Shigdar S, Graham P, John K . Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012; 31(3-4):779-91. DOI: 10.1007/s10555-012-9389-1. View

18.

Chen X, Rycaj K, Liu X, Tang D . New insights into prostate cancer stem cells. Cell Cycle. 2013; 12(4):579-86. PMC: 3594258. DOI: 10.4161/cc.23721. View

19.

Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W . Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway. Int J Biochem Cell Biol. 2013; 45(12):2736-48. DOI: 10.1016/j.biocel.2013.09.008. View

20.

Fossa S, Nilssen Y, Kvale R, Hernes E, Axcrona K, Moller B . Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience. Urology. 2013; 83(1):146-52. DOI: 10.1016/j.urology.2013.08.081. View